Lutetium
Research stageRecent clinical, regulatory, research and industry developments relating to this drug.
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- Clinical cancer research : an official journal of the American Association for Cancer Research1
- Journal of nuclear medicine : official publication, Society of Nuclear Medicine1
- Radiology1
- Signal transduction and targeted therapy1
- The New England journal of medicine1
- Herrmann K3
- Rahbar K3
- Chen H2
- Chen X2
- de Bono J2
- Fizazi K2
- Fu H2
- Guo W2
- Clinical Imaging Research Centre2
- Department of Nuclear Medicine and Minnan PET Center2
- Institute of Molecular and Cell Biology2
- Xiamen Cancer Center2
- College of Design and Engineering1
- From the School of Medicine1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 3 of the same disease areas as Lutetium in the shared literature.
Studied across the same disease area as Lutetium in the shared literature.
Studied across the same disease area as Lutetium in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- Europe PMC — research literature